Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST).

IF 5 2区医学 Q1 HEMATOLOGY

Thrombosis and haemostasis Pub Date : 2025-01-21 DOI:10.1055/a-2501-1369

Virginie Barbay, Yohann Repessé, Dominique Desprez, Nicolas Drillaud, Birgit Frotscher, Marie-Léa Piel-Julian, Sabine Castet, Fabienne Genre-Volot, Brigitte Tardy, Annie Harroche, Corinne Gandossi, Meriem Zidi, Sara Carlsson, Nana Kragh, Eva Bednar, Claude Négrier, Aurélien Lebreton

{"title":"Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST).","authors":"Virginie Barbay, Yohann Repessé, Dominique Desprez, Nicolas Drillaud, Birgit Frotscher, Marie-Léa Piel-Julian, Sabine Castet, Fabienne Genre-Volot, Brigitte Tardy, Annie Harroche, Corinne Gandossi, Meriem Zidi, Sara Carlsson, Nana Kragh, Eva Bednar, Claude Négrier, Aurélien Lebreton","doi":"10.1055/a-2501-1369","DOIUrl":null,"url":null,"abstract":"Background: The Hemophilia Functional Ability Scoring Tool (Hemo-FAST), consisting of a patient-reported outcome (PRO) part and a clinician-reported outcome (ClinRO) part, was developed as a rapid and effective tool to assess functional mobility in clinical practice. This study (NCT04731701) aimed to validate the psychometric properties of Hemo-FAST for assessment of joint health in people with haemophilia (PwH).Methods: PwH A or B aged ≥18 years completed questionnaires including the PRO part of Hemo-FAST and the short-form 36 health survey (SF-36) during one study visit. Clinicians completed the Haemophilia Joint Health Score (HJHS) and the ClinRO part of Hemo-FAST at the same visit. Validation was performed using reliability, construct validity, and structure validity assessments.Results: The study enrolled 180 PwH A or B from 14 centres across France. Estimated time to complete the PRO part was mean (standard deviation) 4.6 (5.4) minutes. PRO items showed good test-retest reliability (intraclass correlation coefficient value ≥0.70). Inter-rater values were >0.70 for 7/9 ClinRO items, indicating good reliability. All items (15 PRO; 9 ClinRO) had high internal consistency (Cronbach's coefficient alpha: 0.97). Hemo-FAST demonstrated convergent construct validity with HJHS and the SF-36 physical component and discriminant construct validity with the SF-36 mental health component. Hemo-FAST scores distinguished between subgroups of people with expected differences in joint health status, including by haemophilia severity (p < 0.0001).Conclusion: This study successfully validated Hemo-FAST as a rapid and reliable tool for the functional assessment of joint health in adults with haemophilia, both in clinical practice and clinical research settings.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis and haemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2501-1369","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Hemophilia Functional Ability Scoring Tool (Hemo-FAST), consisting of a patient-reported outcome (PRO) part and a clinician-reported outcome (ClinRO) part, was developed as a rapid and effective tool to assess functional mobility in clinical practice. This study (NCT04731701) aimed to validate the psychometric properties of Hemo-FAST for assessment of joint health in people with haemophilia (PwH).

Methods: PwH A or B aged ≥18 years completed questionnaires including the PRO part of Hemo-FAST and the short-form 36 health survey (SF-36) during one study visit. Clinicians completed the Haemophilia Joint Health Score (HJHS) and the ClinRO part of Hemo-FAST at the same visit. Validation was performed using reliability, construct validity, and structure validity assessments.

Results: The study enrolled 180 PwH A or B from 14 centres across France. Estimated time to complete the PRO part was mean (standard deviation) 4.6 (5.4) minutes. PRO items showed good test-retest reliability (intraclass correlation coefficient value ≥0.70). Inter-rater values were >0.70 for 7/9 ClinRO items, indicating good reliability. All items (15 PRO; 9 ClinRO) had high internal consistency (Cronbach's coefficient alpha: 0.97). Hemo-FAST demonstrated convergent construct validity with HJHS and the SF-36 physical component and discriminant construct validity with the SF-36 mental health component. Hemo-FAST scores distinguished between subgroups of people with expected differences in joint health status, including by haemophilia severity (p < 0.0001).

Conclusion: This study successfully validated Hemo-FAST as a rapid and reliable tool for the functional assessment of joint health in adults with haemophilia, both in clinical practice and clinical research settings.

查看原文本刊更多论文

血友病功能能力评分工具（Hemo-FAST）的心理测量学验证。

血友病功能能力评分工具（Hemo-FAST）由患者报告的结果（PRO）部分和临床报告的结果（ClinRO）部分组成，是一种快速有效的评估临床实践中功能流动性的工具。本研究（NCT04731701）旨在验证Hemo-FAST的心理测量特性，以评估血友病（PwH）患者的关节健康。方法：年龄≥18岁的PwH A或B在一次研究访问中完成问卷调查，包括Hemo-FAST PRO部分和SF-36简短健康调查（SF-36）。临床医生在同一次访问中完成血友病关节健康评分（HJHS）和Hemo-FAST的ClinRO部分。采用信度、结构效度和结构效度评估进行验证。结果：该研究招募了来自法国14个中心的180名PwH A或B。完成PRO部分的估计时间为平均（标准差）4.6（5.4）分钟。PRO项目具有良好的重测信度（类内相关系数值≥0.70）。7/9个ClinRO项目的评分间值为0.70，信度较好。所有项目(15 PRO；9 ClinRO)具有较高的内部一致性（Cronbach's系数α: 0.97）。Hemo-FAST对HJHS和SF-36身体成分具有趋同效度，对SF-36心理健康成分具有区别效度。根据血友病的严重程度，Hemo-FAST评分可以区分不同亚组患者的关节健康状况(p结论：该研究在临床实践和临床研究中成功验证了Hemo-FAST是一种快速可靠的血友病成人关节健康功能评估工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thrombosis and haemostasis 医学-外周血管病

CiteScore

11.90

自引率

9.00%

发文量

140

审稿时长

1 months

期刊介绍： Thrombosis and Haemostasis publishes reports on basic, translational and clinical research dedicated to novel results and highest quality in any area of thrombosis and haemostasis, vascular biology and medicine, inflammation and infection, platelet and leukocyte biology, from genetic, molecular & cellular studies, diagnostic, therapeutic & preventative studies to high-level translational and clinical research. The journal provides position and guideline papers, state-of-the-art papers, expert analysis and commentaries, and dedicated theme issues covering recent developments and key topics in the field.